The core of the problem lies in how piperine actually works. It does not primarily help nutrients cross the intestinal wall. Instead, it inhibits the body’s machinery for eliminating foreign compounds, including the liver enzyme CYP3A4, the related enzyme CYP2C9, and the efflux transporter P-glycoprotein. These systems act as shared metabolic gatekeepers for a large fraction of orally administered drugs. When piperine blocks them, co-administered substances accumulate in the bloodstream, whether or not they are the intended target. The author, Masaki Kaneko of KYB Medical Service and KYB Orthogenics in Tokyo, compares the mechanism to the well-known food–drug interactions caused by grapefruit juice and St. John’s wort, both of which also modulate CYP3A4 activity.

The clinical consequences are not hypothetical. In controlled human pharmacokinetic studies, ten days of piperine at 20 milligrams per day increased the area under the concentration–time curve of the anticonvulsant carbamazepine by about 48 percent. In patients with epilepsy, single doses of piperine significantly raised carbamazepine concentrations and prolonged its half-life, and piperine also increased exposure to the anticonvulsant phenytoin. For the anti-inflammatory drug diclofenac, co-administration increased drug exposure by roughly 66 percent and extended its half-life by 34 percent, consistent with CYP2C9 inhibition. Physiologically based pharmacokinetic modeling predicts that 20 milligrams of piperine daily would raise exposure to several CYP3A4 substrates by more than 25 percent, including increases of about 34 percent for nifedipine, 35 percent for cyclosporine, and 59 percent for simvastatin. The greatest concern involves narrow-therapeutic-index drugs such as phenytoin and carbamazepine, where even modest increases in blood levels can trigger toxicity, including nystagmus and ataxia. Similar caution applies to anticoagulants, digoxin, and immunosuppressants.

Of the 14 tabulated drug-interaction studies, 12 showed increased exposure to the co-administered medication, spanning rifampicin, propranolol, theophylline, nevirapine, midazolam, chlorzoxazone, and fexofenadine. Two exceptions are instructive. A two-day course of a combined curcuminoid–piperine preparation did not alter the pharmacokinetics of midazolam, flurbiprofen, or paracetamol, whereas three days of piperine alone increased midazolam exposure, a discrepancy that remains unexplained. And in breast cancer patients, curcumin plus piperine reduced exposure to endoxifen, the active metabolite of tamoxifen, by 12.4 percent, showing that the direction of an interaction cannot be assumed to be an increase.

The nutrient side of the evidence tells a strikingly different story. Kaneko compiled a structured summary of 22 human pharmacokinetic studies and classified them by funding and affiliation. Nearly all the studies reporting enhanced absorption of nutrients or phytochemicals were conducted or funded by the manufacturer of the piperine ingredient, enrolled small numbers of healthy volunteers, and used plasma concentration as a surrogate endpoint. The celebrated 2,000 percent curcumin figure was calculated against a baseline so low that curcumin given alone was barely detectable in the assay. For beta-carotene, a 14-day crossover study in men with low baseline values showed a greater serum response with piperine, and for coenzyme Q10 only the 21-day, 120-milligram arm showed an increase of about 30 percent, with shorter comparisons showing no significant effect. For vitamin B6, selenium, and vitamin C, the human evidence exists, as far as the author could determine, only in manufacturer summaries or conference abstracts rather than peer-reviewed reports.

Independent trials have largely failed to confirm the enhancement claims. In three crossover studies of curcumin formulations involving 12, 30, and 9 healthy adults, piperine-containing preparations did not differ significantly from native curcumin or standard extract. Solubility-based approaches performed far better: in one trial, micellar formulations achieved 57-fold higher curcumin exposure and gamma-cyclodextrin complexes 30-fold higher, without any piperine at all. When researchers measured unconjugated curcumin separately, it remained below 2 nanomolar in most participants even after 2,280 milligrams of curcumin with 20 milligrams of piperine, suggesting that earlier studies measuring total curcumin, conjugated and unconjugated together, may have overstated the effect. For resveratrol, 20 milligrams of piperine left plasma concentrations of the parent compound and its metabolites unchanged. A 2025 three-arm study drove the point home: curcuminoid exposure rose dramatically when the proportion of long-pepper extract increased from 1 to 10 percent, yet the high-piperine arm still did not outperform a piperine-free comparator extract given at less than half the curcuminoid dose.

Beyond drug interactions, a subtler hazard arises from inadvertent supplement–supplement combinations. Curcumin appears in small amounts in many blended products marketed for joint, skin, gut, or liver support, so consumers may ingest it without considering themselves turmeric users. If they separately take a piperine-containing supplement, they unknowingly recreate the turmeric–piperine combination that has been linked to liver injury. In a United States registry series of ten adjudicated cases of turmeric-associated liver injury, five patients were hospitalized and one died; three of the seven products analyzed also contained piperine, and the investigators raised the possibility that the combination contributes to rising case numbers, though causation is unproven and absolute incidence appears low. Rising supplement-associated liver injury was highlighted at the 2026 Congress of the European Association for the Study of the Liver, and for context, supplement-related liver failure leading to liver transplant waitlisting in the United States has increased roughly eightfold over the past quarter century.

Kaneko is careful to note that piperine is not inherently a problem ingredient. Its inclusion is scientifically defensible when several conditions are met together: the target ingredient should have a documented bioavailability limitation that is mechanistically addressable by inhibiting first-pass metabolism or efflux, rather than poor solubility; enhancement should have been demonstrated in humans for the specific chemical form and dose used, preferably by independent investigators and, for heavily conjugated compounds, using the unconjugated fraction as the endpoint; the intended population should be defined and should not include people likely to be taking narrow-therapeutic-index drugs metabolized by CYP3A4, CYP2C9, or transported by P-glycoprotein; and the piperine dose should be the lowest shown to be effective, with clear label disclosure. On the evidence reviewed, few current products satisfy the second condition.

The Perspective also challenges assumptions about premium distribution channels. Labels such as “practitioner-exclusive” or “physician-dispensed” are marketing designations, not regulatory categories, and in the author’s observation piperine has now entered Japan’s clinic-dispensed supplement market, where users are especially likely to be taking prescription medications. Japan’s Foods with Function Claims framework operates on a notification system without pharmaceutical-style premarket evaluation, and the good manufacturing practice requirements that became mandatory on 1 September 2026, following the 2024 health-damage cases linked to a functional food product, address manufacturing quality rather than formulation appropriateness. A product can be manufactured to a high standard, free of contamination and accurately labeled, while still being formulated in a scientifically questionable way.

The practical implications reach clinicians, consumers, and industry alike. Clinicians should routinely ask about supplement use, including practitioner-exclusive products, when reviewing medications. Consumers can check labels for “black pepper extract,” “Piper nigrum extract,” “piperine,” or branded piperine ingredients, and should avoid unintentionally combining a piperine-containing supplement with a separate curcumin product. Label warnings advising people on anticonvulsants, anticoagulants, or immunosuppressants to consult a clinician are endorsed as necessary but insufficient, since a warning on one product cannot address risk created by combining two individually innocuous products, and cannot predict whether an interaction will raise or lower drug exposure. Regulators, the author suggests, could require that any “enhanced absorption” claim be backed by human data for the specific form and dose in the product, and pharmacovigilance systems should capture supplement–drug and supplement–supplement co-exposures. The broader message is that supplement formulation should be a deliberate, expert-driven discipline grounded in nutritional science and pharmacology, rather than an accumulation of trending ingredients, and that the ability to explain the rationale for every component is what separates a thoughtfully formulated product from one that is merely well manufactured.

Subject of Research: Piperine as a bioavailability enhancer in dietary supplements and its drug interaction risks

Article Title: Enhancement without a rationale? Black pepper extract (piperine) in dietary supplements and the future of formulation: a perspective from Japan

Article References: Kaneko, M. (2026). Enhancement without a rationale? Black pepper extract (piperine) in dietary supplements and the future of formulation: a perspective from Japan. Frontiers in Nutrition, 13, Article 1981406. https://doi.org/10.3389/fnut.2026.1981406

Image Credits: AI Generated

DOI: 10.3389/fnut.2026.1981406

Keywords: piperine, black pepper extract, dietary supplements, bioavailability, CYP3A4, P-glycoprotein, drug interactions, curcumin, turmeric, liver injury, formulation, Japan

Hepatocellular carcinoma is one of the deadliest cancers worldwide, and its rise is closely tied to chronic liver injury, cirrhosis, and persistent oxidative damage. Because diagnosis often comes late and treatment options are limited, scientists have long been interested in chemoprevention, the idea that compounds taken before disease develops can interrupt the earliest steps of tumor formation. Curcumin has attracted decades of attention for its anti-inflammatory and antioxidant behavior, but it suffers from notoriously poor absorption in the gut. Piperine has a well-documented ability to boost the bioavailability of curcumin, which is why the two are so frequently paired in both traditional cuisine and modern experimental design. The new study set out to test whether that pairing could do more than improve uptake, and whether it could measurably alter the biology of a developing liver tumor.

To model the disease, the researchers induced hepatocellular carcinoma in rats using a two-hit protocol that mirrors how human liver cancer often arises from accumulated toxic insults. Animals first received diethylnitrosamine, or DEN, a potent carcinogen that damages DNA and initiates malignant transformation in hepatocytes. This was followed by thioacetamide, or TAA, a compound that produces repeated cycles of liver injury, fibrosis, and regeneration, creating the inflamed, scarred environment in which initiated cells can proliferate into full tumors. The regimen ran for twenty weeks, a period long enough for tumor burden to become established and measurable. Alongside this carcinogenic exposure, separate groups of rats received oral pretreatment with curcumin alone, piperine alone, or the two compounds in combination, given throughout the entire experimental period.

The damage in the untreated carcinogen group was exactly what the model predicts. Rats exposed to DEN and TAA showed increased tumor burden, sharply elevated liver enzymes in the serum, and a biochemical signature of a liver under siege. Lipid peroxidation, the oxidative degradation of cell membranes, climbed as reactive oxygen species overwhelmed the tissue. The liver’s own antioxidant defenses, the enzymatic systems that normally neutralize free radicals, were depleted. Alpha-fetoprotein, a classic tumor marker for hepatocellular carcinoma, rose in the bloodstream, and interleukin-6, a pro-inflammatory signaling molecule implicated in cancer-promoting chronic inflammation, was elevated as well. Under the microscope, the liver architecture was severely distorted, with the organized lobular structure of healthy tissue replaced by the disarray of injury and nodular transformation.

The treatment groups told a strikingly different story. Rats that received curcumin, and to a greater extent those that received curcumin and piperine together, showed improved levels of the key serum biomarkers, better antioxidant status, and reduced lipid peroxidation. Histopathological examination revealed that the normal tissue structure was substantially restored rather than progressively destroyed. In practical terms, the compounds did not merely mask the damage in blood tests; the livers themselves looked measurably healthier. The combination regimen emerged as the most effective intervention, consistent with the idea that piperine’s enhancement of curcumin’s bioavailability translates into a stronger biological effect when the two are administered together.

The mechanistic heart of the paper lies in what the team found when they probed the TBP2–ASK1–JNK–caspase-3 axis in liver tissue. This signaling cascade begins with TBP2, a thioredoxin-binding protein that responds to oxidative stress, and passes through ASK1, a mitogen-activated protein kinase kinase kinase also known as MAP3K5, which becomes activated when its inhibitory thioredoxin partner is oxidized and released. Activated ASK1 phosphorylates downstream JNK, the c-Jun N-terminal kinase, which in turn influences the mitochondrial pathway of apoptosis, ultimately engaging caspase-3, the executioner enzyme that dismantles the cell. In the carcinogen-exposed rats, this axis was dysregulated, a disruption that matters because the balance of this pathway determines whether damaged cells are eliminated by programmed cell death or allowed to survive and accumulate the mutations that drive cancer.

Preventive treatment with curcumin and piperine normalized the expression of the proteins in this cascade, restoring a pattern of cellular signaling and apoptosis closer to that of healthy liver tissue. The authors interpret this as evidence that the chemopreventive effect of the compounds is not a vague antioxidant blanket but a targeted modulation of a defined stress-response pathway. By damping the oxidative stress that activates ASK1 and rebalancing the apoptotic machinery downstream, the treatment appears to preserve the liver’s ability to clear damaged cells while reducing the inflammatory and peroxidative conditions that fuel tumor growth. Immunohistochemistry and Western blotting provided complementary confirmation, mapping where in the tissue the protein changes occurred and quantifying their abundance.

The study was conducted with formal ethical oversight, approved by the Institutional Animal Ethics Committee of Jamia Hamdard under the guidelines of India’s Committee for the Purpose of Control and Supervision of Experiments on Animals, and the work followed ARRIVE reporting standards for animal research. Data were analyzed by one-way analysis of variance followed by Tukey’s post hoc test, with results considered statistically significant at a threshold of p less than 0.05. The authors received no external funding for the study, and the first author was supported by a Junior Research Fellowship from the University Grants Commission. The article was published open access on 9 October 2026, making the full dataset and methods available to researchers anywhere without a subscription.

As with any animal study, the usual caveats apply. A rat model of chemically induced liver cancer, however well constructed, does not reproduce every feature of human hepatocellular carcinoma, which typically develops over decades against a backdrop of viral hepatitis, alcohol-related injury, or metabolic dysfunction. Doses used in laboratory animals often exceed what a person could reasonably obtain from diet alone, and curcumin’s low bioavailability remains a genuine obstacle to clinical translation even when piperine is present. The authors are careful to frame the findings as chemopreventive and hepatoprotective effects observed in an experimental model, associated with modulation of the TBP2–ASK1–JNK–caspase-3 axis, rather than as a demonstrated therapy for established human tumors.

Nevertheless, the study adds a meaningful piece to a growing body of evidence that dietary bioactive compounds can act on specific, measurable molecular targets rather than exerting only diffuse antioxidant effects. If the TBP2–ASK1–JNK–caspase-3 axis proves to be similarly dysregulated in human liver disease, the curcumin–piperine combination, or optimized derivatives of it, could become candidates for controlled trials aimed at preventing the progression of chronic liver injury toward cancer. For now, the image is an appealing one: two molecules that have traveled together through human kitchens for centuries, shown under the strict lens of modern molecular biology to coordinate a defense of the liver’s most vulnerable signaling machinery. The next step will be determining whether that defense survives the journey from the rat liver to the clinic.

Subject of Research: Chemoprevention of hepatocellular carcinoma by curcumin and piperine through modulation of the TBP2–ASK1–JNK–caspase-3 axis in rats

Article Title: Curcumin and piperine modulate the TBP2-ASK1-JNK-caspase-3 axis associated with prevention of DEN and TAA-induced hepatocellular carcinoma in rats

Article References: Afroz, N., Vafa, A., Ghosh, R., Rahaman, P. F., Wajid, S., & Ahmad, A. (2026). Curcumin and piperine modulate the TBP2-ASK1-JNK-caspase-3 axis associated with prevention of DEN and TAA-induced hepatocellular carcinoma in rats. BMC Cancer. https://doi.org/10.1186/s12885-026-17037-4

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17037-4

Keywords: curcumin, piperine, hepatocellular carcinoma, chemoprevention, liver cancer, oxidative stress, ASK1, JNK, caspase-3, apoptosis, diethylnitrosamine, thioacetamide

Parkinson’s disease affects an estimated 6.1 million people worldwide and roughly 1.04 million Americans, and its hallmark is the progressive death of dopamine-producing neurons in the substantia nigra and striatum. Because the symptoms of tremor, rigidity, bradykinesia and gait disturbance stem largely from dopamine depletion, most current drug strategies attempt to restore dopaminergic signaling. Levodopa therapy remains the gold standard, but long-term use brings considerable complications, so clinicians often pair it with monoamine oxidase B inhibitors such as selegiline. These inhibitors block the flavin-dependent enzyme MAO-B, which breaks down dopamine in the brain, thereby preserving the neurotransmitter and easing motor symptoms. The problem is that existing MAO-B inhibitors carry a heavy burden of side effects, including nausea, insomnia, orthostatic hypotension, hallucinations, serotonin syndrome in severe cases and worsening dyskinesia when combined with levodopa. Safer, more selective alternatives are urgently needed.

The research team turned to nature’s pharmacy. Phytochemicals, and polyphenols in particular, have repeatedly shown antioxidant, anti-inflammatory and neuroprotective properties relevant to neurodegenerative diseases, and piperine has a growing preclinical track record spanning neuroprotective, anticonvulsant and antidepressant effects. Crucially, earlier laboratory work had already shown that piperine can inhibit MAO enzymes directly: one experimental study reported IC50 values of 20.9 micromolar for MAO-A and 7 micromolar for MAO-B, while another documented mixed-type inhibition of MAO-A and competitive inhibition of MAO-B. Derivatives of piperine have shown even more striking selectivity, with one compound inhibiting MAO-B at an IC50 of just 0.045 micromolar. What remained missing was a rigorous, atomistic account of how piperine engages the MAO-B active site and whether that engagement is stable enough to matter therapeutically.

To answer that question, the researchers first docked piperine, whose structure was quantum-mechanically optimized using the B3LYP functional with a 6-31G** basis set, into the crystal structure of human MAO-B, the well-characterized PDB entry 2BYB. Using AutoDock 4.2 with a two-stage blind-and-focused protocol and 200 independent Lamarckian Genetic Algorithm runs, they computed a binding free energy of −9.23 kcal/mol for piperine, substantially better than the −6.3 kcal/mol recorded for Deprenyl. The docked pose placed piperine squarely in the hydrophobic cavity adjacent to the FAD cofactor, forming multiple hydrogen bonds with essential amino acids while its flat, aromatic rings engaged in the kind of pi-pi stacking and hydrophobic contacts that drive high-affinity ligand binding in this enzyme.

Docking, however, is only a static snapshot. To test whether the complex survives the thermal chaos of a real cellular environment, the team ran molecular dynamics simulations in GROMACS 2022.6 with the Amber99SB force field, explicitly solvating the systems in TIP3P water with 0.15 M physiological salt and crucially performing three independent 200-nanosecond replicates per system to capture statistical variability. The results were consistent and telling. The average root mean square deviation of the protein backbone was 0.219 ± 0.017 nm for the MAO-B-piperine complex, tighter than both the free protein at 0.281 ± 0.008 nm and the Deprenyl complex at 0.227 ± 0.002 nm, indicating that piperine binding actually stabilizes the enzyme scaffold. Root mean square fluctuation, radius of gyration and solvent accessible surface area analyses all reinforced the same picture: the piperine-bound system remained compact, stable and free of unfolding across the full simulation window.

The hydrogen bond and contact analyses added further weight. Over 200 nanoseconds, the piperine complex maintained an average of 407 ± 3 protein-protein hydrogen bonds and roughly 2248 ± 15 protein-ligand contacts, versus about 1810 ± 76 contacts for Deprenyl, and the protein-ligand distance held steady near 0.2 nm throughout. Principal component analysis showed that the first two eigenvectors accounted for just over half of the total motion in every system, and that binding piperine constrained and clustered the protein’s motions compared with the free enzyme. The free energy landscape, plotted along the first two principal components, revealed a single deep global minimum for the piperine complex with no signs of aberrant conformational excursions, confirming that the ligand locks the enzyme into a thermodynamically settled state.

The energetic accounting sealed the case. Using the MM-PBSA method, the team calculated a total binding free energy of −142.12 ± 11.34 kJ/mol for the MAO-B-piperine complex against −86.21 ± 11.15 kJ/mol for MAO-B-Deprenyl, with van der Waals forces the dominant favorable contribution. The authors are careful to note an important limitation: Deprenyl is an irreversible inhibitor whose clinical power comes from forming a covalent bond with the FAD cofactor, a step not modeled here, so the comparison reflects noncovalent binding components rather than a direct measure of inhibitory potency in the clinic. Even so, within that framework, piperine’s noncovalent engagement of the MAO-B cavity proved decisively more favorable.

The study also probed the electronic heart of the interaction using density functional theory at the B3LYP/6-311++G(d,p) level. Piperine’s HOMO-LUMO energy gap of 3.76 eV was considerably smaller than the 5.39 eV of the Deprenyl cocrystal system, translating into lower chemical hardness (1.88 versus 2.70), higher softness (0.53 versus 0.37) and a much larger electrophilicity index (3.96 versus 1.82 eV). By the conceptual DFT and hard-soft acid-base logic, a softer, more polarizable molecule like piperine can rearrange its electron density more readily in response to the electrostatic field of the enzyme’s active site, enabling stronger orbital overlap with the electron-rich aromatic residues lining the binding pocket. Its substantially higher dipole moment of 4.46 Debye, versus 0.49 for the cocrystal system, further supports strong orientation-dependent interactions at the binding interface.

Perhaps most importantly for drug development, piperine’s pharmacokinetic profile is genuinely encouraging. SwissADME and pkCSM predictions showed that piperine passes Lipinski’s rule of five with zero violations and also clears the Ghose, Veber, Egan and Muegge filters, with high gastrointestinal absorption and predicted blood-brain barrier permeability, the single most essential property for a central nervous system drug. These predictions align with experimental evidence: in vitro models of the blood-brain barrier have shown piperine achieving the highest penetration among tested analogs, and rat pharmacokinetic studies after oral dosing found a brain-to-plasma concentration ratio near unity, high affinity for brain tissue and rapid, significant brain uptake. In SH-SY5Y neuronal cells, piperine showed no significant toxicity at concentrations up to 40 micromolar and protected the cells against chemically induced damage at moderate doses, hinting at a genuine neuroprotective window.

The caveats are real and the authors state them plainly. Piperine is a known inhibitor of CYP3A4 and P-glycoprotein, which means it can amplify the levels of other medications, a serious concern for Parkinson’s patients who typically take multiple drugs. This study, for all its methodological depth, remains entirely computational, and piperine’s in vivo inhibition of MAO-B at achievable brain concentrations has not yet been demonstrated in animal models or patients. Still, the convergence of docking affinity, simulation stability, binding energetics, favorable quantum chemical reactivity and an experimentally validated brain-penetrant pharmacokinetic profile makes a rare, internally consistent case. If future laboratory and clinical work confirms these predictions, a molecule borrowed from the kitchen spice rack could become the scaffold for a new generation of safer, better-tolerated Parkinson’s therapies.

Subject of Research: MAO-B inhibition for Parkinson's disease using the natural compound piperine, evaluated through molecular docking, molecular dynamics simulation, DFT analysis and pharmacokinetic prediction

Article Title: Therapeutic strategy for Parkinson's disease through MAO-B inhibition by a novel compound: MD simulation, DFT analysis and pharmacokinetic study

Article References: Baziyar, P., & Emamzadeh, R. (2026). Therapeutic strategy for Parkinson's disease through MAO-B inhibition by a novel compound: MD simulation, DFT analysis and pharmacokinetic study. Results in Chemistry, 30, Article 103837. https://doi.org/10.1016/j.rechem.2026.103837

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103837

Keywords: Parkinson's disease, piperine, MAO-B inhibitor, molecular dynamics simulation, molecular docking, DFT analysis, MM-PBSA, pharmacokinetics, neurodegenerative disease, black pepper, dopamine, drug discovery